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Abstract
There are over 100 genes that have been reported to be associated with asthma or related
phenotypes. In 2006–2007 alone there were 53 novel candidate gene associations reported in the
literature. Replication of genetic associations and demonstration of a functional mechanism for the
associated variants are needed to confirm an asthma susceptibility gene. For most of the candidate
genes there is little functional information. In a previous review by Hoffjan et al. published in 2003,
functional information was reported for 40 polymorphisms and here we list another 22 genes
which have such data. Some important genes such as filaggrin, interleukin-13, interleukin-17 and the
cysteinyl leukotriene receptor-1 which not only were replicated by independent association studies
but also have functional data are reviewed in this article.
Background
Asthma is a disease of chronic airway inflammation that
affects nearly 155 million individuals worldwide [1,2].
Like other atopic diseases, asthma is a complex disorder
caused by interactions between multiple genes of small to
modest effect and equally important environmental fac-
tors. Asthma has an important genetic component but no
clear pattern of inheritance, and heritability estimates of
asthma vary between 36–79% [3-5].
It is possible to define a categorical phenotype for studies
of asthma genetics. However, the heterogeneity of the dis-
ease makes this problematic. Therefore, many studies
have used quantitative phenotypes as intermediates e.g.
skin test responses and total or specific serum IgE. In this
case, "affected" individuals can be defined as those
exceeding a certain threshold at the extreme of the distri-
bution. Alternatively, an approach called the quantitative
trait locus (QTL) method allows the entire distribution to
be used in the analysis. Quantitative traits are most likely
due to the influence of several alleles at multiple loci
interacting to cause the phenotype. In a more recent devel-
opment, gene expression array technology has been
employed to use gene expression as an outcome variable.
For example, a genome-wide association of gene expres-
sion was performed by Dixon et al. using a cohort of fam-
ilies with an asthmatic proband [6]. In this study, genes
involved in response to unfolded protein, regulation of
progression though the cell cycle, RNA processing, DNA
repair, immune responses and apoptosis showed highly
heritable traits. In addition, the global map made by the
study will be a excellent resource for selecting candidate
genes [6].
Efforts to identify asthma genes have been carried out in
various laboratories around the world and because of the
complexity and heterogeneity of asthma it has been a
daunting task. Two general approaches have been widely
used to study the genetics of asthma: positional cloning
and candidate gene approaches. The positional cloning
approach in particular has been successful in identifying
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genes for asthma and asthma-associated phenotypes in
recent years.
Multiple genome-wide linkage studies for asthma and
allergy have been performed to date. Linkages have been
found in specific ethnic groups, using different pheno-
types and with various levels of statistical significance.
Most of these regions have been replicated in more than
one study. In particular, human chromosomes 2q33,
5q23-31, 6p24-21, 11q21-13, 12q24-12, and 13q14-12
have received the greatest attention, because these regions
contain a large number of candidate genes [7]. However,
most of these identified chromosomal regions are large,
spanning 10–30 Mb, and contain several plausible candi-
date genes. Fine mapping can be performed in these
linked regions and positional candidate cloning can be
performed using high-throughput sequencing, single
nucleotide polymorphism (SNP) genotyping and linkage
disequilibrium (LD) mapping. This has enabled research-
ers to identify susceptibility genes without prior knowl-
edge of the function of those genes e.g. a disintegrin and
metalloproteinase-33 (ADAM 33), dipeptidyl dipepti-
dase-10, plant homeodomain finger protein-11 and G
protein-coupled receptor-154 [8].
Association studies can be more powerful than linkage
studies in certain circumstances. With the development of
high throughput and accurate technologies for DNA
sequencing and SNP genotyping the number of asthma
candidate genes has increased quickly. Hoffjan et al.
reviewed 64 candidate genes in 2003 [9] and the number
increased to 120 [10] in 2006. There are 53 genes that
were reported to be associated with asthma during
2006–2007 (see Additional file 1). Among them filaggrin
is notable since seven replication studies were published
in independent populations in one year. Another five
genes, PTGER3, MYLK, IL17F, ECP and CYSLTR1 were
replicated by other groups. The genome-wide association
studies currently underway are likely to identify multiple
additional genetic variants that are associated with asthma
and associated traits.
Following candidate gene identification, it is important to
explore the functional consequences of the associated
genetic variation. It is likely that many of the genetic vari-
ants associated with asthma do not have functional con-
sequences but are simply in LD with the causal variants.
For SNPs in coding regions it is possible to predict the
consequences for protein structure and function,
although such predictions have to be empirically verified.
However, most SNPs in the human genome are found in
non-coding DNA. Variants located in promoter regions
may change gene expression by altering transcription fac-
tor binding sites or by other more subtle mechanisms.
Intronic variants may have an effect on the alternate splic-
ing pattern in a given cell or tissue. It has been reported
that non-coding sequence, which accounts for at least
30% of the human genome, has an important unexpected
function since it is a major source of regulatory RNAs in
complex organisms [11,12]. In the 2003 review by Hoff-
jan et al. [9] 40 mutations had reports of functional effects
and here we list other genes which have functional reports
(see Additional file 2).
Recently, another type of genetic variation, structural var-
iations which are mainly found in the form of copy
number variants (CNVs), has attracted a large amount of
interest from complex disease researchers. Structural vari-
ations are widespread in the human genome and may
have more functional impact on phenotypic variation
than SNPs [13]. The high throughput genotyping of struc-
tural variations has become possible. CNVs have already
been shown to be associated with susceptibility to HIV
infection [14], lupus glomerulonephritis [15], and
autoimmune diseases [16,17]. There is no report concern-
ing an association between CNVs and asthma to date but
studies are likely underway.
This review focuses on several genes, which provide exam-
ples of the investigation of asthma and allergy susceptibil-
ity genes.
Asthma susceptibility genes
Filaggrin
Filaggrin (FLG) is a key protein of the epidermis and is
therefore important in the formation of the protective
skin barrier. FLG was initially described as a candidate
gene for atopic dermatitis in 2006 [18]. This was a break-
through discovery because most previous allergy genetics
studies were focused on immunological mechanisms and
this was the first study to show that genetic variants in the
skin defense system are important in allergic pathways.
The skin barrier is part of the innate immune system
which keeps water within the body and prevents the
entrance of pathogens and allergens [19]. With a defective
epidermal barrier allergen may more easily gain entrance
through the skin and thus initiate local and systemic
allergy and predispose to allergic disease.
FLG was initially identified as an ichthyosis vulgaris can-
didate gene in a study of 15 families segregating this single
gene disorder [20]. There are three exons in FLG and two
mutations (R501X and 2282del4) were found in the ich-
thyosis vulgaris patients. Both mutations are in exon 3
and stop protein translation within the first FLG repeat
and result in complete loss of FLG peptide production
[20]. Therefore, these two functional mutations were con-
sidered as the likely causal mutations for ichthyosis vul-
garis in these families. Palmer et al. [18] observed that
many individuals with either of the variations also hadRespiratory Research 2008, 9:4 http://respiratory-research.com/content/9/1/4
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atopic dermatitis or asthma and therefore investigated
whether the two functional variations also contribute to
allergic disease. These authors examined the two muta-
tions in three independent cohorts and found that the
results were consistent in that the two nonsense muta-
tions were highly significantly associated with atopic der-
matitis (AD) but not with asthma [18]. During the
following year these results were replicated by three inde-
pendent studies, two from Germany [21,22] and one from
the UK [23]. In one German study, which included fam-
ily-based and case-control association analyses, the two
mutant alleles showed association with AD as well as
asthma in the context of AD but showed no association
with asthma or the presence of specific IgE in the absence
of AD [22]. Another German study including 476 com-
plete trios (mother, father and affected child) showed
association between extrinsic AD but no association with
intrinsic AD, the latter defined as dermatitis patients who
had normal IgE and lack of sensitization towards environ-
mental allergens [21]. A further study from Germany con-
firmed the association of FLG  variants with AD [24].
Another three studies have shown association of extrinsic
AD, asthma and rhinitis, asthma severity with the FLG var-
iants although in some studies association was only seen
with concomitant AD [21,25,26]. All these data suggest
that the two FLG mutant alleles are important risk factors
for AD but only for asthma when it is found in the context
of AD. An additional seven nonsense or frame shift FLG
mutations were identified in the European population
and two in the Asian population [27]. There were three
reasonably prevalent mutations (in addition to R501X
and 2282del4) that showed association with childhood
eczema [27].
To date there have been no reports showing lack of asso-
ciation of FLG variants and AD. However, the frequency of
the two variants is low (less than 5% in Caucasians) and
they are absent in Asians and Africans, and therefore only
contribute to a small proportion of AD cases [22]. Most
AD cases must be caused by other factors and genes that
affect skin barrier development are good candidates for
further studies.
Interleukin-13
Interleukin-13 (IL13) is a good candidate as an asthma
susceptibility gene because it is a cytokine produced by
Th2 cells and because its genetic location on chromosome
5q31 has been linked to asthma and related phenotypes
in multiple linkage studies [28-34]. This cytokine is capa-
ble of promoting allergen-induced bronchial hyperre-
sponsiveness, epithelial cell damage, goblet cell
hyperplasia with mucus hyperproduction, and eosi-
nophilia. There are several studies that have shown that
common polymorphisms in this gene, i.e. -1111C > T and
+2043G > A (R130Q), are associated with asthma and/or
related phenotypes such as increased total serum IgE,
atopy, and atopic dermatitis [35-41]. Other investigators
have found further evidence for the role of IL13 polymor-
phisms in the pathogenesis of allergic disease [42-46].
Tarazona-Santos et al. resequenced the whole IL13 gene
and confirmed that +2043G > A, which causes replace-
ment of a positively charged arginine (R) with a neutral
glutamine (Q) at position 130, was the only nonsynony-
mous substitution present in all ethnic groups [47]. The
130 position is in the α-helix D segment, which has been
proven to be a region where IL13 interacts with IL4 recep-
tor-α/IL13 receptor-α1 heterodimers [48]. In the study of
Chen et al. the 130Q IL13 variant (named Q110R in that
paper, because the 20-amino acid signal sequence was not
numbered) enhanced IL13-dependent gene induction at
the cellular level and induced more significant bronchial
hyperresponsiveness in mice compared with the 130R
IL13 variant [49]. These authors also found that this func-
tional variant had synergistic effects with other functional
variants, e.g. 50 V and 551R in the IL4 receptor-α gene
[49]. Vladich et al. investigated the function of R130Q in
peripheral blood mononuclear cells from normal donors
[50]. They incubated these cells with the IL13 variants and
compared the STAT6 phosphorylation, CD23 expression,
and hydrocortisone-dependent IgE synthesis. In these
multiple functional assays IL13 130Q showed more activ-
ity than wild type IL13 and was less effectively neutralized
by soluble IL13 receptor-α. From these results the authors
concluded that the +2043G > A polymorphism increased
the activity of IL13 and therefore enhanced the pathways
leading to allergic inflammation [50]. Both of these
papers offered functional evidence demonstrating that the
+2043G > A polymorphism plays an important role in the
pathogenesis of asthma. None of these results are defini-
tive individually but taken together provide strong evi-
dence that IL13 is a susceptibility gene for allergic disease.
Another polymorphism, -1111C > T, is in the IL13 pro-
moter region. This promoter SNP shows low levels of LD
with +2043G > A in most populations [47]. Therefore, the
associations between -1111C > T and asthma-related phe-
notypes [35,41] are likely independent of the +2043G > A
polymorphism. It was observed that the T allele of -1111C
> T had increased binding of a T cell transcription factor
(NFAT), which regulates IL13 and IL4 expression and -
1111TT homozygosity was associated with both asthma
and altered regulation of IL13 production [35]. It is still
unclear whether the two polymorphisms act synergisti-
cally. However, it is possible that the increased transcrip-
tion caused by -1111C > T combined with the enhanced
activity caused by +2043G > A would amplify the IL13-
dependent inflammatory reaction.Respiratory Research 2008, 9:4 http://respiratory-research.com/content/9/1/4
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Interleukin-17F
Unlike IL13, IL17F was discovered recently [51-53]. It is
one member of the IL17 gene family and the coding
sequence contains 7742 bp, including three exons. IL17F
was investigated as an asthma candidate gene because of
its function i.e. IL17F is one of the cytokines produced by
activated mast cells, CD4+ T cells, and basophils and can
upregulate IL6 and IL8 transcripts and protein expression
in primary bronchial epithelial cells [51]. IL17F is
expressed in human liver, lung, and fetal liver tissue [51]
and increased expression was oberserved in the airways of
allergic asthma patients [51]. In addition, IL17F is located
on chromosome 6p, which has been linked to asthma and
asthma-related phenotypes in multiple genome scans
[54,55].
A Japanese case-control study reported an protective asso-
ciation between homozygosity for the nonsynonymous
variant H161R and asthma but no association between
heterozygosity for H161R or IL17F haplotypes and
asthma [56]. Importantly, there were no homozygotes for
161R in the 432 asthma patients (compared with 9
homozygotes in the 435 controls). Kawaguchi et al. [56]
also performed experiments to determine whether H161R
was a functional variant. Recombinant wild type IL17F
(containing histidine at position 161) and mutant IL17F
(containing arginine at position 161) were used to stimu-
late BEAS-2B cells (a human bronchial epithelial cell line)
and the results demonstrated that the mutant IL17F could
not induce activation of a signaling pathway involving
RAF1, MAP2K1/2 and MAPK1/3. The mutant isoform was
also unable to stimulate the production of cytokines e.g.
CSF2 and chemokines e.g. IL8, CXCL1 and CXCL5. More-
over, the mutant IL17F acted as an antagonist of wild type
IL17F to block induction of IL8 expression [56]. However,
despite this strong functional data, the association results
were not replicated by another case-control study [57]. In
this study, the authors genotyped five IL17F SNPs includ-
ing H161R in 1027 white females and found no associa-
tion between any SNP or haplotype with asthma [57]. The
lack of consistency between the two studies may be due to
differences in environmental factors or modifier genes
that influence the H161R association. Thus, the results of
Kawaguchi et al. [56] await confirmation in other popula-
tions and at the in vivo level.
Several additional studies have shed light on the function
of IL17F and further suggested that it is a good candidate
asthma susceptibility gene. It was reported that IL17F was
expressed in bronchial epithelial cells and inflammatory
cells in an allergic asthma mouse model but not in the
lungs of control mice [58]. IL17 induced the expression of
IFN-gamma-induced protein 10 (IP10) in bronchial epi-
thelial cells [59]. IP10 has been shown to be a marker of
virus-induced asthma [60,61]. In addition, the epigenetic
changes in the IL17A-IL17F locus are associated with the
differentiation of the novel T helper subset, TH17 cells
[62].
Cysteinyl leukotriene receptors
Cysteinyl leukotrienes are bronchoconstrictors and proin-
flammatory mediators of the asthma response that act
through two G protein-coupled receptors: cysteinyl leuko-
triene receptor-1 (CYSLTR1) [63] and CYSLTR2 [64]. Both
receptors are the targets of anti-asthmatic drugs. CYSLTR2
maps to chromosome 13q14, approximately 300 kb from
D13S153, which was reported linked to asthma in two
studies [65,66]. The association of CYSLTR2 and asthma
was replicated in two subsequent studies [67,68] and two
functional studies showed potency of leukotriene D4 on
the M202V variant was lower compared with the wild-
type receptor [68,69].
CYSLTR1 is located on chromosome Xq21.1. Five recent
studies reported that SNPs in CYSLTR1 were associated
with allergic phenotypes. Among them, two studies used
Caucasian samples and both of them reported significant
results of the synonymous SNP, 927T > C [70,71]. A dis-
crepancy between these studies is that the results from the
family study [70] showed that the 927T allele had a strong
association with atopy severity in female subjects but the
results from the case-control study showed that the minor
allele, 927C, associated with asthma present with atopic
dermatitis but only in males [71]. A study of a Spanish
population found that the combination of 927T of
CYSLTR1 and -444A of the leukotriene C4 synthase gene
was less common in male patients with asthma than in
controls [72]. CYSLTR1 promoter haplotypes were associ-
ated with aspirin-sensitive asthma in a Korean popula-
tion, but again only in male patients [73]. CYSLTR1
promoter haplotypes have also been associated with func-
tional effects [73,74]. The 927T > C SNP is in strong LD
with the promoter SNPs both in Caucasian and Asian
populations in the HapMap database [75]. Consequently,
the five studies effectively examined the same haplotype.
In the Korean studies, they found that the haplotype con-
taining the minor alleles of the promoter SNPs increased
the promoter activity in three cell lines: Jurkat, A549, and
U937 cells [73,74]. This result is consistent with another
paper in which the U937 cell line was used [76]. Further-
more, at the -475A > C promoter SNP, the A allele was
found to bind a specific protein that was not bound by the
C allele [74]. However, another study found a contradic-
tory result in THP1 cells [77]. The authors found that the
G allele of promoter SNP -336A > G (the minor allele) was
associated with a twofold decrease in luciferase expression
[77]. The discrepancy may have resulted from the use of
different cell lines or the length of the constructs. There-
fore, more studies are needed to validate these results.Respiratory Research 2008, 9:4 http://respiratory-research.com/content/9/1/4
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A further complication is that the precise location of the
CYSLTR1 promoter region is still unclear. In three papers
[73,76,77] 5'RACE was performed using cDNA from
human fetus and human leukocytes and no novel exon
was found. However, in another paper two novel
upstream exons were found before the previously
described exon 1 using cDNA from U937 and THP-1 cells
and the promoter region was identified in the region
between -125 bp to -786 bp upstream of the novel exons
[78]. It is possible that there are two alternative promoters
in CYSLTR1 and they initiate different transcripts. There
are no reports of any SNPs in the new promoter region.
ORMDL3
In a genome-wide association study performed by Moffatt
et al. SNPs in the 17q21 region showed a strong associa-
tion with childhood asthma in both a UK family cohort
and German case-control samples. Furthermore, the
results were replicated in two independent cohorts [79].
The authors also measured global gene expression in
Epstein-Barr virus-transformed lymphoblastoid cells from
children in their genotyped family samples and found
that the markers which showed strongest association with
asthma were also consistently associated with transcript
levels of ORMDL3 [79]. No other transcript levels were
associated with these markers. In this study, the markers
which showed association are in different LD blocks so it
is possible that multiple functional variants independ-
ently contribute to the disease susceptibility. There are
also many structural variants in this region that may con-
tribute to the pathogenesis of asthma. This study is
remarkable due to the use of genome-wide association
analysis coupled with genome-wide gene expression anal-
ysis.
ORMDL3 is a poorly characterized gene and the underly-
ing mechanism for the association with asthma is unclear.
ORMDL3 is a member of a family of endoplasmic reticu-
lum membrane proteins and has a ubiquitous pattern of
expression in humans and Drosophila. It encodes trans-
membrane proteins anchored in the endoplasmic reticu-
lum and shows conservation across species [80].
Conclusion
The pathogenesis of asthma, a complex disease, involves
gene-gene interactions as well as gene-environment inter-
actions. Multiple modest risk factors work synergistically
to influence asthma disease susceptibility. The number of
asthma-susceptibility genes identified by genetic studies is
still increasing. However, most studies lack information
on the mechanism by which the SNPs lead to asthma. Elu-
cidating the functional consequences of SNPs is essential
to confirm association results and to understand how the
SNPs combine to influence susceptibility. Eventually,
results from this important field are expected to improve
preventive strategies and to aid in the development of
diagnostic tools and therapies.
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